July 15, 2026- HORIBA is proud to announce the expansion of its U.S. diagnostic laboratory portfolio through a new strategic partnership with MEDCONN Diagnostics. The distribution of the MEDCONN MQ-3000 and MQ-8000 systems strengthens the commitment of HORIBA to advancing diabetes testing solutions and enhancing clinical laboratory capabilities across the United States.
The MEDCONN MQ-3000 and MQ-8000 Glycated Hemoglobin Analyzers complement HORIBA’s existing diabetes testing portfolio by providing laboratories with additional flexibility and efficiency in managing testing workflows. Together, these systems support reliable, high-quality diagnostic performance while expanding access to solutions designed to meet the evolving needs of clinical laboratories.
“The MEDCONN MQ-3000 and MQ-8000 systems are a natural complement to our current offering and reinforce our commitment to providing laboratories with innovative, reliable solutions that support improved patient care,” said Scott Dowdakin, Senior Director, Commercial Operations, HORIBA Instruments Incorporated. “Expanding our portfolio with these systems reflects our continued focus on advancing diabetes diagnostics.”
The addition of the MQ-3000 and MQ-8000 systems builds on HORIBA’s established expertise in diagnostic instrumentation, further strengthening its ability to support laboratories with comprehensive, end-to-end solutions. By enhancing its diabetes testing portfolio, HORIBA aims to help laboratories optimize efficiency, scalability, and diagnostic confidence. HORIBA is actively preparing for product commercialization to support a seamless introduction into clinical laboratory environments.
The MEDCONN MQ-3000 and MQ-8000 systems are expected to be commercially available in the United States in the summer of 2026.